Related Experiment Video
Updated: Jul 9, 2026

Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
Published on: July 17, 2012
Longitudinal tracking of FTLD: toward developing clinical trial methodology
David S Knopman1, Bradley S Boeve, Richard J Caselli
1Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA. knopman@mayo.edu
Abstract:
Putative treatments for the frontotemporal lobar degenerations are likely to become available for testing in clinical trials in the next few years. To design clinical trials for this group of disorders, a number of conceptual, methodologic, and diagnostic issues must be resolved. This presentation reviews diagnostic criteria, instruments for longitudinal study, questions about study duration, and the possible uses of biomarkers in clinical trials. In addition, a multicenter trial is described in which some aspects of diagnosis and longitudinal measurement in the frontotemporal lobar degenerations are being specifically explored.
More Related Videos
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11:11Longitudinal Measurement of Extracellular Matrix Rigidity in 3D Tumor Models Using Particle-tracking Microrheology
Published on: June 10, 2014
Related Concept Videos
Longitudinal Studies
Clinical Trials: Overview
Longitudinal Research
Clinical Trials
There are four phases in a clinical trial. A phase one...
Preclinical Development: Overview